ArticleMolecular imaging
RGD-human serum albumin conjugates as efficient tumor targeting probes.
Article in Molecular imaging. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- HighFold: accurately predicting structures of cyclic peptides and complexes with head-to-tail and disulfide bridge constraints.Briefings in bioinformatics · 2024Article
- Article
- Cyclic peptide drugs approved in the last two decades (2001-2021).RSC chemical biology · 2022Review
- Development of Improved Tumor-Residualizing, GRPR-Targeted Agents: Preclinical Comparison of an Endolysosomal Trapping Approach in Agonistic and Antagonistic Constructs.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- Mechanistic insights into the pH-dependent membrane peptide ATRAM.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Development of individualized anti-metastasis strategies by engineering nanomedicines.Chemical Society reviews · 2015Review
- Nuclear molecular imaging with nanoparticles: radiochemistry, applications and translation.The British journal of radiology · 2015Review
- Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology.Theranostics · 2014Review
- Progress in molecular imaging in endoscopy and endomicroscopy for cancer imaging.Journal of healthcare engineering · 2013Review
- Albumin-binding domain conjugate for near-infrared fluorescence lymphatic imaging.Molecular imaging and biology · 2012Article
- HSA coated iron oxide nanoparticles as drug delivery vehicles for cancer therapy.Molecular pharmaceutics · 2011Article
- Molecular Imaging Probe Development using Microfluidics.Current organic synthesis · 2011Article
- Synthesis and in vivo fate of zwitterionic near-infrared fluorophores.Angewandte Chemie (International ed. in English) · 2011Article
- Optical image-guided surgery--where do we stand?Molecular imaging and biology · 2011Review
- Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting.Bioconjugate chemistry · 2011Article
- PET/NIRF/MRI triple functional iron oxide nanoparticles.Biomaterials · 2010Article
- Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors.Breast cancer research : BCR · 2010Article
- Gadolinium-based contrast agents for magnetic resonance cancer imaging.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
- Emerging Biomimetic Drug Delivery Nanoparticles Inspired by Extracellular Vesicles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Cyclic arginine-glycine-aspartate (RGD) peptides and their derivatives have been intensively studied as tumor targeting probes. One major drawback, however, is their short blood circulation half-lives, which greatly compromises their targeting efficacy. To address this issue, a cyclic peptide, c(RGDyK), and an organic dye (IRDye800 or Cy5.5) were covalently conjugated onto human serum albumin (HSA). The conjugates were subjected to in vitro cell staining, in vivo near-infrared fluorescence (NIRF) imaging, ex vivo NIRF imaging, and histologic studies to evaluate their feasibility as tumor imaging probes. As a control, RAD peptide was also coupled with HSA and labeled with IRDye800 for in vivo imaging. The HSA-RGD-IRDye800 exhibited integrin alpha(v)beta(3)-specific binding in cell staining experiment. In vivo NIRF imaging showed higher tumor accumulation and tumor to background contrast of HSA-RGD-IRDye800 over RGD-IRDye800. The integrin specificity of HSA-RGD-IRDye800 is confirmed by both successful inhibition of tumor uptake in the presence of c(RGDyK) and the inability to accumulate in integrin-positive tumors by RAD-HSA-IRDye800. Histologic examination revealed initial tumor vascular binding and eventually both tumor vasculature and tumor cell integrin binding in vivo. In summary, we successfully developed an RGD-based protein conjugate with prolonged circulation half-life for NIRF imaging of tumor integrin alpha(v)beta(3) expression. The success of this study may be generalizable for other peptide-based probes to be conjugated with HSA for prolonged tumor contrast and improved pharmacokinetics.
Indexed as
Identifiers
19397852PMC6366843W2106631160What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.